{"schema_version":"secwatch.filing_event.v1","accession":"0001175680-26-000002","form_type":"8-K","ticker":"CYDY","cik":"0001175680","company_name":"CytoDyn Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.036132+00:00","generated_at":"2026-05-15T00:33:39.540112+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"CytoDyn holds investor call for corporate and clinical update; no material results disclosed in filing","bullets":["Company held investor call on April 30, 2026 at 1:00 p.m. PT to provide corporate and clinical update.","Presentation materials furnished as Exhibit 99.1 titled 'Leronlimab – A Novel Therapeutic in CCR5+ Immuno-Oncology'.","No specific financial or trial data included in the 8-K or exhibit; update is forward-looking without new quantitative details."],"urls":{"canonical":"https://secwatch.observer/filing/0001175680-26-000002","json":"https://secwatch.observer/filing/0001175680-26-000002.json","markdown":"https://secwatch.observer/filing/0001175680-26-000002.md","text":"https://secwatch.observer/filing/0001175680-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175680/000117568026000002/0001175680-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175680/000117568026000002/ck0001175680-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:33:39.540112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}